Immune proteins activation at ALS diagnosis linked to progression
Researchers detected changes in the production of several immune signaling proteins, called cytokines, in the cerebrospinal fluid (CSF) — the…
Articles by Steve Bryson, PhD
Mayo Clinic awarded $22M grant to study ibudilast in ALS patients
A $22 million federal grant to the Mayo Clinic in Florida will fund a study providing access to the investigational…
Analysis IDs 4 patient groups with distinct ALS progression patterns
A computer analysis using real-world data from an amyotrophic lateral sclerosis (ALS) clinic identified four groups of patients with…
New ALS gene mutation found in families in Spain: Study
A new genetic mutation that may cause amyotrophic lateral sclerosis (ALS) has been discovered in families living in La…
Phase 2 trial planned for IRX4204, targeting neuroinflammation
Io Therapeutics is planning to launch a Phase 2 trial into its investigational oral therapy IRX4204 in people…
New B-cell therapy eases disease severity, delays onset: Study
Repeat infusions of naive immune B-cells were safe and delayed disease onset, reduced disease severity, and extended survival in animal…
Little benefit seen in ALS with nonpharmacological treatment for pain
The use of nonpharmacological treatment — interventions such as muscle exercise, aerobics, and strength training — did not significantly ease…
COYA 302 slows disease progression, lowers biomarkers: Trial
COYA 302, Coya Therapeutics’ experimental immune-modulating combination therapy, safely slows disease progression and reduces levels of disease biomarkers in…
ALS patients treated by neurologists receive better care: Medicare study
People with amyotrophic lateral sclerosis (ALS) who are treated by a neurologist are more likely to receive evidence-based care…
Scientists propose delta-FS as new measure of disease severity in ALS
A new amyotrophic lateral sclerosis (ALS) assessment called delta-FS — defined as the rate of decline over time in…